XVIPF (Xvivo Perfusion AB) Total Assets: $264.99 Mil (As of Mar. 2026)


XVIPF Xvivo Perfusion AB XVIPF
91 GF Score
Price $29.00
GF Value $42.07
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB Total Assets?

Xvivo Perfusion AB XVIPF -1.32% 91 Total Assets is $264.99 Mil as of Mar. 2026. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Xvivo Perfusion AB's Total Assets for the quarter that ended in Mar. 2026 was $264.99 Mil.

During the past 12 months, Xvivo Perfusion AB's average Total Assets Growth Rate was 9.20% per year. During the past 3 years, the average Total Assets Growth Rate was 11.90% per year. During the past 5 years, the average Total Assets Growth Rate was 20.60% per year. During the past 10 years, the average Total Assets Growth Rate was 29.20% per year.

During the past 13 years, Xvivo Perfusion AB's highest 3-Year average Total Assets Growth Rate was 46.20%. The lowest was 11.90%. And the median was 31.30%.

Total Assets is connected with ROA %. Xvivo Perfusion AB's annualized ROA % for the quarter that ended in Mar. 2026 was 5.99%. Total Assets is also linked to Revenue through Asset Turnover. Xvivo Perfusion AB's Asset Turnover for the quarter that ended in Mar. 2026 was 0.10.

Xvivo Perfusion AB  (OTCPK:XVIPF) Total Assets Explanation

Total Assets is connected with ROA %.

Xvivo Perfusion AB's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=15.584/( (255.459+264.991)/ 2 )
=15.584/260.225
=5.99 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Xvivo Perfusion AB's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=25.861/( (255.459+264.991)/ 2 )
=25.861/260.225
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Xvivo Perfusion AB Total Assets Related Terms

Xvivo Perfusion AB Total Assets Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB Total Assets Chart

Xvivo Perfusion AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 169.71 167.00 214.05 218.73 255.46

Xvivo Perfusion AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 226.50 250.04 253.63 255.46 264.99
XVIPF
91GF Score
Xvivo Perfusion AB XVIPF
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Xvivo Perfusion AB's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=227.413+28.047
=255.46

Xvivo Perfusion AB's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=232.835+32.156
=264.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $264.99 Mil mean?
Xvivo Perfusion AB (XVIPF) has a Total Assets of $264.99 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's Total Assets too high?
Xvivo Perfusion AB's current Total Assets is $264.99 Mil. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Total Assets compare to ABT and SYK?
Xvivo Perfusion AB's Total Assets of $264.99 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Devices & Instruments company?
A good Total Assets depends on the Medical Devices & Instruments industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Total Assets is $264.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current Total Assets is $264.99 Mil. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Total Assets is $264.99 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for XVIPF:

  • Total Assets: $264.99 Mil
  • GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score

Get the complete analysis for XVIPF

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.00
Price
$42.07
GF Value